Novel Antiviral Blocks CMV After Stem Cell Tx – MedPage Today
|
Novel Antiviral Blocks CMV After Stem Cell Tx
MedPage Today The safety profile is a key feature, given that the antiviral approved for CMV infection prophylaxis in solid-organ transplant (valganciclovir [Valcyte]) is limited by myelosuppression, particularly in the setting of hematopoietic-cell transplantation … Novel drug prevents common viral disease in stem–cell transplant patients …Medical Xpress Antiviral Protects Against CMV After Stem Cell TransplantsMedscape CMX001 reduced cytomegalovirus disease after HSCTHealio |
